Islet Regeneration and Pancreatic Duct Glands in Human and Experimental Diabetes

• DOI: 10.3389/fcell.2022.814165
• Publication Date: 2022-02-04T16:22:56Z
• Authors: Diletta Overi; Guido Carpino; Marta Moretti; Antonio Franchitto; Lorenzo Nevi; Paolo Onori; Enrico De Smaele; Luca Federici; Daniele Santorelli; Marella Maroder; Lola M. Reid; Vincenzo Cardinale; Domenico Alvaro; Eugenio Gaudio
• Keywords: PDX1; Pancreatic Islets

Contrasting evidence is present regarding the contribution of stem/progenitor cell populations to pancreatic regeneration in diabetes. Interestingly, a compartment with features has been identified duct glands (PDGs). The aims study were evaluate islet injury and regeneration, participation PDG type 2 diabetic mellitus (T2DM) an experimental model Human pancreata obtained from normal (N = 5) or T2DM 10) cadaveric organ donors. Experimental diabetes was generated mice by intraperitoneal injection 150 mg/kg streptozotocin (STZ, N 10); 10 STZ also received daily injections 100 µg human recombinant PDX1 peptide (STZ + PDX1). Samples examined immunohistochemistry/immunofluorescence RT-qPCR. Serum glucose c-peptide levels measured mice. Islets patients showed β-cell loss, signs proliferation, higher proportion central islets. PDGs had percentage proliferating insulin+ glucagon+ cells compared controls; islets could be observed within walls patients. characterized reduced area controls. treatment increased untreated but did not revert In conclusion, show involvement niche. administration support endocrine STZ. These findings contribute defining role compartments pancreas.